UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, focusing on innovative treatments for severe diseases in immunology and neurology.

About

Related projects

Projects

Learn more

NEMO

    R&D Advanced Therapies Biopharma

En cours

Learn more

GTRP-DIAT

    R&D Advanced Therapies

En cours

Learn more

Targetum

    R&D Biopharma

Terminé

Related news

News

Learn more

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

    Press release

19.05.2025

Learn more
UCB2

RYSTIGGO® (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support

    Press release

09.05.2025